MetaCap

Alvotech (ALVO) vs Vor Biopharma (VOR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vor Biopharma (VOR) has outperformed Alvotech (ALVO) over the past year, gaining 157.6% versus a loss of 19.8%. Alvotech is the larger company by market cap ($1.47 billion vs $1.18 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALVO-19.84%VOR+157.58%
+251%+98%-56%
Nov 21, 20251 yearNov 20, 2026
ALVO-57.53%VOR-79.67%
+73%-16%-105%
Jun 13, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALVO versus VOR key metrics
MetricALVOVOR
Share price$4.12$19.19
Market cap$1.47B$1.18B
1-day change-3.96%+3.62%
YTD return-19.69%+46.71%
1-year return-19.84%+157.58%
5-year return—-92.00%
P/E ratio (TTM)—0.06
Forward P/E19.46—
EPS (TTM)$-0.82$300.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$586.32M—
Revenue growth (YoY)+19.74%—
Net income (latest FY)$27.92M$-695.98M
Gross margin59.82%—
Operating margin13.34%—
Net margin4.76%—
52-week high$6.53$26.00
52-week low$2.94$7.21
Distance from 52-week high-36.91%-26.19%
Analyst consensusbuystrong_buy
Avg. price target upside+82.04%+103.23%
Average volume1.13M945.67K
Shares outstanding356.82M61.43M
Employees1,27976
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VOR has outperformed ALVO by 177.4 percentage points over the past year.

About Alvotech

ALVO stock →

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees

About Vor Biopharma

VOR stock →

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees

ALVO vs VOR FAQ

Which is bigger, Alvotech or Vor Biopharma?

Alvotech (ALVO) is larger, with a market capitalization of $1.47B compared with $1.18B for Vor Biopharma (VOR).

Which stock has performed better over the past year, ALVO or VOR?

VOR returned +157.58% over the past 12 months, compared with -19.84% for ALVO (price return, excluding dividends). Past performance does not predict future results.

Are Alvotech and Vor Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons